Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 11/20 | 0.53 |
| ▸ | CTRC | Q99895 | 8/20 | 0.53 |
| ▸ | ELANE | P08246 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804111 | 0.99 | CMA1 (0.53) | CMA1CTRCELANEKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL6805327 | 0.99 | CMA1 (0.53) | CMA1CTRCELANEKDM4EHSD17B10 | |
| SCHEMBL6804071 | 0.89 | ELANE (0.50) | CMA1CTRCELANEHSD17B10 | |
| SCHEMBL6799136 | 0.87 | ELANE (0.47) | CMA1CTRCELANEHSD17B10 | |
| SCHEMBL6802606 | 0.87 | ELANE (0.47) | CMA1CTRCELANEKDM4EHSD17B10 | |
| SCHEMBL6803001 | 0.87 | ELANE (0.60) | CMA1CTRCELANE | |
| SCHEMBL6804114 | 0.87 | CMA1 (0.51) | CMA1CTRCELANE | |
| SCHEMBL6810206 | 0.86 | CTRC (0.50) | CMA1CTRCELANE | |
| SCHEMBL6804164 | 0.85 | CMA1 (0.48) | CMA1CTRCELANE | |
| SCHEMBL30765599 | 0.85 | CTRC (0.54) | CMA1CTRCELANEKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | claimed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20050165234-A1 | Process for preparing pyrimidine compound | AJINOMOTO CO. INC (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1553090-A1 | PROCESS FOR PRODUCING PYRIMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-6906068-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165234-A1 | Process for preparing pyrimidine compound | SERPINB1, CMA1, CTRC | CMA1 2/4885CTRC 3/4885ELANE 27/4885 |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | DPYD, NUDT1, UMPS | CMA1 1079/4885CTRC 2595/4885ELANE 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.